

综述

凝集素样氧化低密度脂蛋白受体1作为动脉硬化性心血管疾病新干预靶点的研究进展

徐索文, 刘培庆

(中山大学药学院药理毒理学实验室, 广东 广州 510006)

收稿日期 2010-9-23 修回日期 网络版发布日期 2011-8-17 接受日期 2011-2-17

摘要 凝集素样氧化低密度脂蛋白受体1 (LOX-1) 是1997年发现的氧化低密度脂蛋白 (oxLDL) 受体, 属于E族清道夫受体家族, 它可以结合、内化、降解oxLDL。LOX-1具有介导内皮细胞功能失调、平滑肌细胞凋亡、巨噬细胞泡沫化与炎症以及不稳定斑块的形成等功能。由此可见, LOX-1参与了动脉硬化发生发展的各个环节, 有望成为动脉硬化性心血管疾病治疗的新靶点。近年来, 可溶性LOX-1的检测有助于动脉硬化相关疾病的预防。本文对LOX-1的表达调控及其在动脉粥样硬化发生发展中的作用进行综述。

关键词 [凝集素样氧化低密度脂蛋白受体1](#) [氧化低密度脂蛋白](#) [动脉粥样硬化](#)

分类号 [R963](#)

Progress in lectin-like oxidized LDL receptor-1 as a novel therapeutic target in atherosclerotic cardiovascular diseases

XU Suo-wen, LIU Pei-qing

(Department of Pharmacology and Toxicology, School of Pharmaceutical Sciences, Sun Yat-sen University, Guangzhou 510006, China)

Abstract

Lectin-like oxidized LDL receptor-1 (LOX-1), a newly identified vascular receptor for oxLDL, belongs to E-class scavenger receptor which is involved in the binding, internalization and degradation of oxLDL. LOX-1 also mediates several central events in atherosclerosis: endothelial dysfunction, the apoptosis of smooth muscle cells, macrophage-derived foam cell formation, inflammation and plaque rupture. Taken together, LOX-1 participates in each phases of the development of atherosclerosis and thus could be a potential therapeutic target for the management of atherosclerosis. Recently, soluble LOX-1 has been a useful diagnostic biomarker in atherosclerosis-related cardiovascular disorders. This paper reviews the regulation of LOX-1 and the crucial role of LOX-1 in the development of atherogenesis.

Key words [lectin-like oxidized LDL receptor-1](#) [oxidized LDL](#) [atherosclerosis](#)

DOI: 10.3867/j.issn.1000-3002.2011.03.014

通讯作者 刘培庆 liupq@mail.sysu.edu.cn

扩展功能

本文信息

- ▶ [Supporting info](#)
- ▶ [PDF\(416KB\)](#)
- ▶ [\[HTML全文\]\(0KB\)](#)
- ▶ [参考文献](#)

服务与反馈

- ▶ [把本文推荐给朋友](#)
- ▶ [加入我的书架](#)
- ▶ [加入引用管理器](#)
- ▶ [复制索引](#)
- ▶ [Email Alert](#)
- ▶ [文章反馈](#)
- ▶ [浏览反馈信息](#)

相关信息

- ▶ [本刊中 包含 “凝集素样氧化低密度脂蛋白受体1”的 相关文章](#)
- ▶ 本文作者相关文章

- [徐索文](#)
- [刘培庆](#)